symptoms; sometimes, she (he) might continue to manifest significant symptoms, even though decisions about
the “medical necessity” of ongoing inpatient care tend to
be governed mainly by issues of safety and imminent danger. (See this article at CurrentPsychiatry.com for a Table
of considerations when making the transition from the
acute phase to the continuation phase of treatment.20,24,25)
To minimize risk of relapse, psycho-education should
include discussion of:
• Psychiatrically deleterious effects of alcohol and il-
licit drug use
• Suicide risk, including what to do in an emergency
• Protecting a regular sleep schedule and avoiding
• The potential for poor medication adherence and
management of side effects
• The need for periodic laboratory monitoring, as
• The role of adjunctive psychotherapy and effective
• Familiarity with symptoms that serve as warning
signs, and how to monitor their onset.
Dr. Goldberg is a consultant to Merck & Co. and Sunovion.
He is a member of the speakers’ bureau of AstraZeneca,
Janssen, Merck & Co., Takeda and Lundbeck, and Sunovion. Dr. Ernst reports no financial relationships with any
company whose products are mentioned in this article or
with manufacturers of competing products.
The opinions expressed herein are those of the authors and
do not necessarily reflect those of Federal Practitioner,
Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review
complete prescribing information for specific drugs or drug
combinations—including indications, contraindications,
warnings, and adverse effects—before administering pharmacologic therapy to patients.
1. Goldberg JF, Garno JL, Callahan AM, et al. Overdiagnosis of bipolar disorder
among substance use disorder in patients with mood instability. J Clin Psychiatry.
2. Rosa AR, Cruz B, Franco C, et al. Why do clinicians maintain antidepressants in
some patients with acute mania? Hints from the European Mania in Bipolar Lon-
gitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin
3. Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and
symptomatic recovery among bipolar depressed patients with concomitant manic
symptoms: findings from the STEP-BD. Am J Psychiatry. 2007;164(9):1348-1355.
4. Bowers MB Jr, McKay BG, Mazure CM. Discontinuation of antidepressants in newly admitted psychotic patients. J Neuropsychiatr Clin Neurosci.
5. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of
mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry.
6. Geller B, Zimmerman B, Williams M, et al. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry.
7. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially
hospitalized for unipolar depression. Am J Psychiatry. 2001;158(8):1265-1270.
8. Yatham LN, Kauer-Sant’Anna M, Bond DJ, et al. Course and outcome after the
first manic episode in patients with bipolar disorder: prospective 12-month data
from the Systematic Treatment Optimization Project for Early Mania project. Can J
9. Chaudron LH, Pies RW. The relationship between postpartum psychosis and bipolar disorder: a review. J Clin Psychiatry 2003;64(11):1284-1292.
10. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-
11. Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in
bipolar disorders. Bipolar Disord. 2009;11(15):453-473.
12. Schulze TG, Hedeker D, Zandi P, et al. What is familial about familial bipolar
disorder? Resemblance among relatives across a broad spectrum of phenotypic characteristics. Arch Gen Psychiatry. 2006;63(12):1368-1376.
13. Song J, Bergen SE, Kuja-Halkola R, et al. Bipolar disorder and its relation to
major psychiatric disorders: a family-based study in the Swedish population.
Bipolar Disord. 2015;7(2):184-193.
14. Goes FS, Sadler B, Toolan J, et al. Psychotic features in bipolar and unipolar
depression. Bipolar Disord. 2007;9(8):901-906.
15. Fiedorowicz JG, Endicott J, Solomon DA, et al. Course of illness following
prospectively observed mania or hypomania in individuals presenting with
unipolar depression. Bipolar Disord. 2007;14(6):664-671.
16. Tansey KE, Guipponi M, Domenici E, et al. Genetic susceptibility for bipolar
disorder and response to antidepressants in major depressive disorder. Am J
Med Genetics B Neuropsychiatr Genet. 2014;165B(1):77-83.
17. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode
Mania Study: prediction of recovery and first recurrence. Am J Psychiatry.
18. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus
Conference Panel on medication treatment of bipolar disorder 2000. J Clin
19. Keck PE Jr, Perlis RH, Otto MW, et al. The Expert Consensus Guideline
Series: treatment of bipolar disorder 2004. Postgrad Med Special Report.
20. Goldberg JF, Ghaemi SN. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disord.
21. Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar
depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(2):
22. MacQueen GM, Trevor Young L, Marriott M, et al. Previous mood state predicts
response and switch rates in patients with bipolar depression. Acta Psychiatr
23. Solomon DA, Leon AC, Coryell WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry. 2010;67(4):339-347.
24. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser
alone. Br J Psychiatry. 2004;184:337-345.
25. Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I
disorder: results from a North American study of quetiapine in combination with
lithium or divalproex (trial 127). Am J Psychiatry. 2009;166(4):476-488.